Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related macular degeneration. Lancet. 2008;372:1835–45.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379:1728–38.

Article  PubMed  Google Scholar 

Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49.

Article  PubMed  Google Scholar 

Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.

Article  PubMed  Google Scholar 

Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94:2–13.

Article  PubMed  CAS  Google Scholar 

Nguyen QD, Heier J, Brown D, Ho A, Kaiser P, Vitti R, et al. Randomized, Double-masked, active-controlled phase 3 trial of the Efficacy and Safety of Intravitreal VEGF trap-Eye in Wet AMD: one-year results of the View-1 study. Investig Ophthalmol Vis Sci. 2011;52:3073.

Google Scholar 

Schmidt-Erfurth U, Chong V, Kirchhof B, Korobelnik J-F, Papp A, Anderesi M, et al. Primary results of an International Phase III Study using Intravitreal VEGF trap-Eye compared to Ranibizumab in patients with wet AMD (VIEW 2). Investig Ophthalmol Vis Sci. 2011;52:1650.

Google Scholar 

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, Multicenter, Randomized, double-masked trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:72–84.

Article  PubMed  Google Scholar 

Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related Macular Degeneration: Therapeutic Management and New-Upcoming approaches. Int J Mol Sci. 2020;21:8242.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2021;128:1050–9.

Article  PubMed  Google Scholar 

Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti-vascular endothelial growth factor therapy in Neovascular Age-Related Macular Degeneration in the United States. Ophthalmol Retina. 2018;2:645–53.

Article  PubMed  Google Scholar 

Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in Neovascular Age-Related Macular Degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4:19–30.

Article  PubMed  Google Scholar 

Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: a retrospective, real-world evidence study of patients with Neovascular Age-Related Macular Degeneration in the United States. Ophthalmol Retina. 2020;4:122–33.

Article  PubMed  Google Scholar 

Bulirsch LM, Saßmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021;106:1288–294.

Article  PubMed  Google Scholar 

Montesel A, Bucolo C, Sallo FB, Eandi CM. Short-term efficacy and safety outcomes of Brolucizumab in the real-life clinical practice. Front Pharmacol. 2021;12:720345.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yeom H, Kwon HJ, Kim YJ, Lee J, Yoon YH, Lee JY. Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration. Sci Rep. 2023;13:11400.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144–67.

Article  PubMed  Google Scholar 

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab using a treat-and-extend regimen: FLUID Study 24-Month results. Ophthalmology. 2019;126:723–34.

Article  PubMed  Google Scholar 

Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, et al. Macular Morphology and visual acuity in Year five of the comparison of Age-related Macular Degeneration treatments trials. Ophthalmology. 2019;126:252–60.

Article  PubMed  Google Scholar 

Siedlecki J, Fischer C, Schworm B, Kreutzer TC, Luft N, Kortuem KU, et al. Impact of Sub-retinal Fluid on the long-term incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under treat & extend anti-vascular endothelial growth factor inhibitors. Sci Rep. 2020;10:8036.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61.

Article  PubMed  Google Scholar 

Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, et al. Incidence and growth of Geographic Atrophy during 5 years of comparison of age-related Macular Degeneration treatments trials. Ophthalmology. 2017;124:97–104.

Article  PubMed  Google Scholar 

Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018;125:878–86.

Article  PubMed  Google Scholar 

Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29:721–31.

Article  PubMed  CAS  Google Scholar 

Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85:425–30.

Article  PubMed  CAS  Google Scholar 

Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–70.

Article  PubMed  Google Scholar 

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, et al. Subfoveal Choroidal thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: twelve-Month results. Ophthalmology. 2016;123:617–24.

Article  PubMed  Google Scholar 

Zarbin MA, Hill L, Maunz A, Gliem M, Stoilov I. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. Br J Ophthalmol. 2021;106:1561–6.

Article  PubMed  Google Scholar 

Lim RH, Gupta B, Simcock P. Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab. Int J Ophthalmol. 2017;10:423–6.

PubMed  PubMed Central  Google Scholar 

Enríquez AB, Baumal CR, Crane AM, Witkin AJ, Lally DR, Liang MC, et al. Early experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021;139:441–8.

Article  PubMed  Google Scholar 

Inoda S, Takahashi H, Maruyama-Inoue M, Ikeda S, Sekiryu T, Itagaki K, et al. Incidence and risk factors of intraocular inflammation after Brolucizumab Treatment in Japan: a Multicenter AMD Study. Retina. 2024;44:714–22.

PubMed  CAS  Google Scholar 

Chakraborty D, Maiti A, Sheth JU, Boral S, Mondal S, Nandi K, et al. Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World experience: the BRAILLE Study. Clin Ophthalmol. 2021;15:3787–95.

Article  PubMed  PubMed Central  Google Scholar 

Bodaghi B, Souied EH, Tadayoni R, Weber M, Ponthieux A, Kodjikian L. Detection and management of intraocular inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2023;7:879–91.

Article